Effects of a novel pea protein hydrolysate on hypertension and chronic kidney disease


Rotimi E. Aluko, alukor@cc.umanitoba.ca and Harold M. Aukema, aukemahm@cc.umanitoba.ca. Human Nutritional Sciences, University of Manitoba, H515-190 Dysart Road, Winnipeg, MB R3T 2N2, Canada
A pea protein hydrolysate (PPH) with renin and angiotensin converting enzyme (ACE) inhibitory activities was used as a potential modulator of the renin-angiotensin system. The diet of rats that have polycystic kidney disease (PKD) was supplemented with 0.5 and 1% levels of the PPH during an 8-week feeding trial. Blood pressure was determined weekly from 4-8 weeks while urine output was measured on week 8. Results showed that the PPH significantly (p<0.05) reduced blood pressure that is associated with PKD. There were no changes in the measured ACE activity in plasma and lungs. However, level of angiotensin II was significantly lower (p<0.05) in groups fed PPH. In terms of kidney function, administration of PPH significantly increased (p<0.05) urine output. PPH also increased level of the desirable cyclooxygenase-1 in kidney tissues. We concluded that PPH had desirable bioactive properties that could ameliorate the intensity of negative symptoms associated with kidney disease.